Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11845768 | 0.76 | SMN1; SMN2 (0.47) | ALDH1A1SMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL8198684 | 0.75 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL8328379 | 0.73 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2GAAHTTHDAC1 | |
| SCHEMBL28725932 | 0.72 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL2197500 | 0.70 | GAA (0.40) | ALDH1A1SMN1; SMN2KMT2AGAAKDM4E | |
| SCHEMBL2199236 | 0.70 | GAA (0.38) | ALDH1A1KMT2AMEN1GAAKDM4E | |
| SCHEMBL7447435 | 0.70 | SLC18A3 (0.58) | ALDH1A1SMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL3751183 | 0.69 | ALDH1A1 (0.74) | ALDH1A1KMT2AMEN1GAAHDAC1 | |
| SCHEMBL28782680 | 0.69 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL2227916 | 0.68 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | ALDH1A1 1476/4885SMN1; SMN2 4368/4885KMT2A 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.